Indian Pharma exports to US may increase in 2018, Care Ratings
The Dollar Business Bureau Despite many hurdles, pricing pressures and competition from other major pharma producing countries, India’s pharma exports to the US will in all likelihood increase in 2017-18. Drugs worth $50bn are expected to become off-patented this year giving enough room for pharma exports to get a boost, a report by Care Ratings revealed. The Indian Pharma industry is likely to face stiff competition from other countries to get Abbreviated New Drug Application(ANDA) approval. Other than this the pricing pressure is likely to increase in the generics market due to the consolidation of distribution channels and increase in competition the report detailed. However due to gain in the sales of generics drugs with branded drugs going off patent during 2017-19, will ...
Sun Pharma to sell 2 plants to Frontida BioPharm
The Dollar Business Bureau Sun Pharmaceutical on Monday announced that it is planning to sell its two oral solid dosage manufacturing plants to Frontida BioPharm Inc in the United States. “Frontida has agreed to continue manufacturing certain products for Sun Pharma at these facilities on a contract basis for a predetermined period. It has also agreed to offer employment to all production, quality and administrative personnel at the sites,” Gurgaon-based pharma company said in a statement. “The effect of this deal on Sun Pharmaceutical’s overall financials and activities is not material,” it added. The drug major also stated it was aware about ensuring the continued supply of quality products to patients during the divestment process. This is the second divestment ...
Generic drug market to cross $27.9 billion by 2020: study
The Dollar Business Bureau India’s generic drug market is expected to cross $27.9 billion and would account for 85% share in the domestic drug market by 2020, according to a study undertaken by ASSOCHAM and RNCOS. The current generic market size is $13.1 billion and is growing at a CAGR of about 16.3%, primarily due to approval granted by the USFDA makers and 21 drugs patent losing licenses by 2019, the study said. “Generic drugs account for 75% of the domestic pharmaceutical market by value. Drugs for cholesterol control, pain management, anticoagulant, respiratory, liver disorders, depression and lipid regulators are highly prevalent in the global market,” said the Associated Chambers of Commerce and Industry of India (ASSOCHAM) and RNCOS. The study was conducted on ‘Generic ...
